[go: up one dir, main page]

NO20072206L - Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens - Google Patents

Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens

Info

Publication number
NO20072206L
NO20072206L NO20072206A NO20072206A NO20072206L NO 20072206 L NO20072206 L NO 20072206L NO 20072206 A NO20072206 A NO 20072206A NO 20072206 A NO20072206 A NO 20072206A NO 20072206 L NO20072206 L NO 20072206L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
amyloid
investigating
procedures
Prior art date
Application number
NO20072206A
Other languages
English (en)
Inventor
Shigeo Takayama
Yuji Yamada
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20072206L publication Critical patent/NO20072206L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541—Double or second antibody, i.e. precipitating antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Den foreliggende oppfinnelsen har til hensikt å konstruere en prosess for å måle ß-amyloid i en biologisk prøve, slik som blod, og å anvende denne prosessen for å diagnostisere Alzheimer's sykdom. Det er mulig å analysere Alzheimer's sykdom ved å måle den totale mengden av ß-amyloid 1-42 og ß-amyloid 1-42 fragmenter, hvorav hver av dem bibeholder et C-terminalt sete tilhørende ß-amyloid 1-42 i den biologiske prøven, ved hjelp av et immunologisk assay, i hvilket et antistoff som gjenkjenner det C-terminal setet til ß-amyloid 1-42 blir avbenyttet. Det er foretrukket at det immunologiske assayet er et kompetitivt immunologisk assay.
NO20072206A 2004-10-28 2007-04-30 Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens NO20072206L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004314639 2004-10-28
JP2005052003 2005-02-25
PCT/JP2005/019787 WO2006046644A1 (ja) 2004-10-28 2005-10-27 アルツハイマー病の検定方法及び診断試薬

Publications (1)

Publication Number Publication Date
NO20072206L true NO20072206L (no) 2007-07-30

Family

ID=36227886

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072206A NO20072206L (no) 2004-10-28 2007-04-30 Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens

Country Status (13)

Country Link
US (1) US20080199879A1 (no)
EP (1) EP1813947A4 (no)
JP (1) JPWO2006046644A1 (no)
KR (1) KR20070073778A (no)
CN (1) CN101048662A (no)
AU (1) AU2005297854A1 (no)
BR (1) BRPI0516674A (no)
CA (1) CA2585148A1 (no)
IL (1) IL182540A0 (no)
MX (1) MX2007005053A (no)
NO (1) NO20072206L (no)
RU (1) RU2007119535A (no)
WO (1) WO2006046644A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
JP5419131B2 (ja) 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ１〜４２特異的モノクローナル抗体
WO2007119685A1 (ja) * 2006-04-13 2007-10-25 Sanko Junyaku Co., Ltd. β－アミロイドの血中分解速度測定によるアルツハイマー病の検定方法及び診断試薬
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
JP4683298B2 (ja) * 2006-08-21 2011-05-18 アイシン精機株式会社 被検物質の免疫測定方法、及び免疫結合親和性解析の制御方法
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
WO2009016734A1 (ja) * 2007-07-31 2009-02-05 University Of Tsukuba 軽度認知機能障害の検定方法
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
WO2009057664A1 (ja) * 2007-10-29 2009-05-07 Mitsubishi Chemical Corporation 抗体及びその利用
WO2010034072A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP5745531B2 (ja) 2009-12-11 2015-07-08 アラクロン・ビオテック・エセ・エレ アミロイドベータペプチドの検出を改善するための方法および試薬
WO2011092796A1 (ja) * 2010-01-28 2011-08-04 パナソニック株式会社 アミロイドβ測定方法
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2012142300A2 (en) * 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US9541561B2 (en) 2012-06-14 2017-01-10 Electronics And Telecommunications Research Institute Method for diagnosing Alzheimer's disease using biomaterial
JP5991666B2 (ja) * 2012-07-04 2016-09-14 公立大学法人大阪市立大学 アルツハイマー病を検出する方法及びキット
JP2016103980A (ja) * 2013-03-08 2016-06-09 パナソニックヘルスケア株式会社 ハイブリドーマ及びモノクローナル抗体
US11360098B2 (en) * 2015-09-28 2022-06-14 Quest Diagnostics Investments Llc Amyloid beta detection by mass spectrometry
WO2017141881A1 (ja) * 2016-02-15 2017-08-24 ノーベルファーマ株式会社 遺伝性疾患に関わるタンパク質の測定方法及び測定キット
EP3242134A1 (en) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2022197651A1 (en) * 2021-03-16 2022-09-22 Neurovision Imaging, Inc. Biofluid-based methods for diagnosing alzheimer's disease-associated conditions
CN113311153B (zh) * 2021-05-12 2023-05-26 华中科技大学 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411974A1 (en) * 1989-07-05 1991-02-06 N.V. Innogenetics S.A. Monoclonal antibodies to a neurofibrillary tangle antigen
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
EP1270592B1 (de) * 2001-06-12 2004-09-29 Wiltfang, Jens Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa
US7135307B2 (en) * 2001-08-10 2006-11-14 Merck & Co., Inc. Gamma three protease
AU2003225636A1 (en) * 2002-03-05 2003-09-22 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein

Also Published As

Publication number Publication date
EP1813947A4 (en) 2008-06-11
KR20070073778A (ko) 2007-07-10
US20080199879A1 (en) 2008-08-21
WO2006046644A1 (ja) 2006-05-04
MX2007005053A (es) 2007-06-19
IL182540A0 (en) 2007-09-20
JPWO2006046644A1 (ja) 2008-05-22
BRPI0516674A (pt) 2008-09-16
CA2585148A1 (en) 2006-05-04
RU2007119535A (ru) 2008-12-10
AU2005297854A1 (en) 2006-05-04
EP1813947A1 (en) 2007-08-01
CN101048662A (zh) 2007-10-03

Similar Documents

Publication Publication Date Title
NO20072206L (no) Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens
Lista et al. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease
Portelius et al. An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid
Liu et al. Epidemiology of environmental exposure and malignant mesothelioma
Zetterberg et al. Fluid markers of traumatic brain injury
Dedong et al. Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients
Nutu et al. Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders
US9709573B2 (en) Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
ATE411525T1 (de) Nachweis einer histonmodifikation in zellfreien nukleosomen
BRPI0619748A8 (pt) anticorpo monoclonal, polinucleotídeo, região variável de cadeia leve, região variável de cadeia pesada, composição, mistura, métodos para produzir um anticorpo, para preparar uma composição farmacêutica ou uma mistura, de diagnóstico de uma doença ou condição associada a amilóide, para determinar o grau de carga de placa amiloidogênica em um tecido, para diagnosticar uma predisposição para uma doença ou condição, para monitorar doença residual mínima e para prever responsabilidade de um paciente, uso de um anticorpo monoclonal e/ou uma parte funcional do mesmo e/ou uma composição farmacêutica ou uma mistura, linhagem celular de hibridoma, e, kits de teste
EP1977234A4 (en) MOLECULES FOR THE TREATMENT OF PULMONARY DISEASE INVOLVING AN IMMUNE RESPONSE TO A CONNECTIVE TISSUE IN THE LUNG
DK3171174T3 (en) Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease
JP2010537200A (ja) 改善されたアルツハイマー診断法
NO20050186L (no) Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser
EP4252243A2 (en) Non-invasive assessment of alzheimer's disease
DK1535076T3 (da) Polypeptid-biomarkörer til diagnose af Alzheimers sygdom
WO2010084327A3 (en) Methods
EP2507637A1 (en) Amyloid beta aggregates in cerebro spinal fluid as biomarkers for alzheimer's disease
Matteussi et al. Age estimation in humans through the analysis of aspartic acid racemization from teeth: A scoping review of methods, outcomes, and open research questions
BR112022000322A2 (pt) Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer
DE502006008028D1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
Peters et al. A computational resource for the prediction of peptide binding to Indian rhesus macaque MHC class I molecules
Rogeberg et al. Identification of amyloid beta mid-domain fragments in human cerebrospinal fluid
BR0115131A (pt) Teste de urina para a diagnose de doenças de priÈnio